Ideaya Biosciences Inc. CEO Yujiro Hata told BioWorld Today that "you'd be hard pressed to find a more personalized-medicine approach to cancer" than synthetic lethality, and his firm hopes to build on proof of concept brought about by the approval of Astrazeneca plc's poly ADP-ribose polymerase (PARP) inhibitor Lynparza (olaparib) in BRCA-mutated advanced ovarian cancer. "We're not looking to develop a PARP inhibitor," he said, discussing the firm's $46 million series A round. "We're focused on what we calling PARP 2.0," aiming to "extend the genetic signature beyond BRCA."
Genes are called synthetic-lethal if the mutation of either of them by itself is deemed viable but a change in two or more together causes cell death. The approach will be investigated in genetically defined patient populations with an eye to exploiting